Iterum Therapeutics
Iterum Therapeutics
ITRM
NASDAQ
1.18
USD
-20.81%
About
Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world.
It is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation. Sulopenem is a potent, thiopenem antibiotic delivered intravenously, which is active against bacteria that belong to the group of organisms known as gram-negatives and causes urinary tract and intra-abdominal infections.
It has also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid. Sulopenem also has an IV formulation. Sulopenem has demonstrated potent in vitro activity against a variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 255.1K |
| Three Month Average Volume | 5.2M |
| High Low | |
| Fifty-Two Week High | 2.5 USD |
| Fifty-Two Week Low | 0.622 USD |
| Fifty-Two Week High Date | 27 Nov 2023 |
| Fifty-Two Week Low Date | 25 Oct 2023 |
| Price and Volume | |
| Current Price | 1.18 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | -6.92% |
| Thirteen Week Relative Price Change | -26.50% |
| Twenty-Six Week Relative Price Change | -17.45% |
| Fifty-Two Week Relative Price Change | 7.01% |
| Year-to-Date Relative Price Change | -49.42% |
| Price Change | |
| One Day Price Change | 4.42% |
| Thirteen Week Price Change | -21.33% |
| Twenty-Six Week Price Change | -9.23% |
| Five Day Price Change | -2.48% |
| Fifty-Two Week Price Change | 34.09% |
| Year-to-Date Price Change | -40.10% |
| Month-to-Date Price Change | -1.26% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | -0.47433 USD |
| Book Value Per Share (Most Recent Quarter) | -0.65804 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | -0.47433 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -0.65804 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -2.56766 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -2.96019 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.99708 USD |
| Normalized (Last Fiscal Year) | -2.96019 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -2.96019 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.99708 USD |
| Including Extraordinary Items (Last Fiscal Year) | -2.96019 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.99708 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 1.77272 USD |
| Cash Per Share (Most Recent Quarter) | 0.70652 USD |
| Cash Flow Per Share (Last Fiscal Year) | -2.82518 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.88609 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -2.8826 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -568,287 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -882,970.30% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -692,954.10% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -890,554.10% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -32.09% |
| Total Debt (5 Year) | 6.10% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 68.09% |
| EPS Change (Trailing Twelve Months) | 55.81% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 9.5M |
| Net Debt (Last Fiscal Year) | -4,974,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 24 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 24 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | -100,000 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | -100,000 |
| Long Term Debt to Equity (Most Recent Quarter) | -100,000 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 2 |
| Current Ratio (Most Recent Quarter) | 1 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -39,343,000 |
| Free Cash Flow (Trailing Twelve Months) | -41,947,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | -100,000 |
| Total Debt to Equity (Most Recent Quarter) | -100,000 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -82.44% |
| Return on Assets (Trailing Twelve Months) | -86.93% |
| Return on Assets (5 Year) | -118.12% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -355.35% |
| Return on Equity (Trailing Twelve Months) | -99,999.99% |
| Return on Equity (5 Year) | -967.84% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -108.84% |
| Return on Investment (Trailing Twelve Months) | -150.76% |
| Return on Investment (5 Year) | -199.23% |